Cardiff Oncology Inc - Company Profile
Powered by 
All the data and insights you need on Cardiff Oncology Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Cardiff Oncology Inc Strategy Report
- Understand Cardiff Oncology Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Cardiff Oncology Inc (Cardiff Oncology), formerly Trovagene Inc is a clinical-stage biotechnology company that focuses on developing drugs which target cell division (mitosis) using precision cancer medicine (PCM) approach for the treatment of hematologic and solid tumor cancers. The company lead product candidate is Onvansertib (previously known as PCM-075), an oral and adenosine triphosphate (ATP) competitive inhibitor of polo-like kinase 1 (PLK1) enzyme. The company is being developed in combination with chemotherapies and targeted therapeutics for treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC), metastatic Castration-Resistant Prostate Cancer (mCRPC) and second-line KRAS mutation-metastatic Colorectal Cancer (mCRC). Onvansertib is being evaluated in three clinical trials, namely, TROV-052, TROV-053, and TROV-054. Cardiff Oncology is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
11055 Flintkote Ave, San Diego, California, 92121-1220
Website
cardiffoncology.com
Telephone
1 858 9527570
No of Employees
31
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CRDF (NASD)
Revenue (2022)
$488,000
26.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-7.1%
(2022 vs 2021)
Market Cap*
$250.6M
Net Profit Margin (2022)
XYZ
15.3%
(2022 vs 2021)
* As of and is in US$
Cardiff Oncology Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Onvansertib + Avastin/FOLFIRI –mCRC Second-Line KRAS-Mutated Metastatic Colorectal Cancer |
| Onvansertib +_ Zytiga/Prednisone – mCRPC Metastatic Castration-Resistant Prostate Cancer |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Cardiff Oncology Inc | GSK plc | Boehringer Ingelheim International GmbH | Traws Pharma Inc | Dana-Farber Cancer Institute Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United Kingdom | Germany | United States of America | United States of America |
| City | San Diego | Brentford | Ingelheim am Rhein | Newtown | Boston |
| State/Province | California | England | Rheinland-Pfalz | Pennsylvania | Massachusetts |
| No. of Employees | 31 | 70,212 | 53,000 | 16 | - |
| Entity Type | Public | Public | Private | Public | Institution |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Rodney S. Markin, M.D., Ph.D. | Chairman | Executive Board | 2020 | 66 |
| Mark Erlander, Ph.D. | Director; Chief Executive Officer | Executive Board | 2020 | 63 |
| James E. Levine | Chief Financial Officer | Senior Management | 2021 | 52 |
| Vicki Kelemen | Executive Vice President; Chief Operating Officer | Senior Management | 2020 | - |
| Fairooz F. Kabbinavar, MD | Chief Medical Officer | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward